Univest
Univest
  • Markets

3 Garments Exporter, Generic Pharma Maker and Batteries and Defence Electronics Maker Stocks With a Strong Future Roadmap: Pearl Global Industries, Strides Pharma Science and HBL Engineering

  • November 16, 2026
  • Posted by: Ankit Jaiswal
  • Category: Best Stocks
No Comments
3 Garments Exporter, Generic Pharma Maker and Batteries and Defence Electronics Maker Stocks With a Strong Future Roadmap: Pearl Global Industries, Strides Pharma Science and HBL Engineering

Pearl Global Industries, Strides Pharma Science and HBL Engineering: ROE of 17.9% to 36.8% and FY22 to FY26 revenue CAGR of 11.8% to 28.0%. Prices as of 13 Nov 2026.

Quick Answer

The three apparel export, pharma and defence cell stocks to watch are Pearl Global Industries, Strides Pharma Science and HBL Engineering. Their return on equity ranges from 17.9% to 36.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 28.0%. HBL Engineering leads on both return on equity at 36.8% and revenue growth at 28.0% a year. Prices are based on the 13 November 2026 close, and this article is educational, not investment advice.

Apparel export, pharma and defence cell stocks give investors a way to track businesses that sit close to everyday demand in India. Pearl Global Industries, Strides Pharma Science and HBL Engineering cover a garments exporter, a generic pharma maker and a batteries and defence electronics maker.

This list covers three apparel export, pharma and defence cell stocks with complete current figures: Pearl Global Industries, Strides Pharma Science and HBL Engineering. Every figure comes from the latest reported financials and the 13 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Apparel Export, Pharma and Defence Cell Stocks?
  • Apparel Export, Pharma and Defence Cell Stocks at a Glance
  • Why Do Apparel Export, Pharma and Defence Cell Stocks Have a Strong Roadmap in India?
  • Why Pearl Global Industries Features Among These Apparel Export, Pharma and Defence Cell Stocks
  • Why Strides Pharma Science Features Among These Apparel Export, Pharma and Defence Cell Stocks
  • Why HBL Engineering Features Among These Apparel Export, Pharma and Defence Cell Stocks
  • Pearl Global Industries vs Strides Pharma Science vs HBL Engineering on Key Financials
  • Key Risks to Check Before Investing in Apparel Export, Pharma and Defence Cell Stocks
  • Final Thoughts on Apparel Export, Pharma and Defence Cell Stocks
    • What are apparel export, pharma and defence cell stocks?
    • Which apparel export, pharma and defence cell stocks are covered in this list?
    • Why do apparel export, pharma and defence cell stocks have a strong future roadmap in India?
    • How has Pearl Global Industries performed financially?
    • How has Strides Pharma Science performed financially?
    • How has HBL Engineering performed financially?
    • What risks should investors check before buying apparel export, pharma and defence cell stocks?
    • Is this list of apparel export, pharma and defence cell stocks investment advice?

What Are Apparel Export, Pharma and Defence Cell Stocks?

Apparel export, pharma and defence cell stocks are listed companies that design and export readymade garments to global brands, make generic medicines and ingredients, and make industrial batteries, defence electronics and railway safety systems. Their earnings depend on export orders, medicine demand and defence and rail orders.

Apparel Export, Pharma and Defence Cell Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Pearl Global Industries 1,333.1 11,806 38.9 35.2 19.0 0.65
Strides Pharma Science 1,014.6 9,491 15.0 36.0 17.9 0.57
HBL Engineering 799.55 22,507 28.8 36.9 36.8 0.03

On valuation, Strides Pharma Science and HBL Engineering trade at a P/E below the industry P/E, while Pearl Global Industries trades above it, which reflects the growth the market already expects. Readers comparing apparel export, pharma and defence cell stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in apparel export, pharma and defence cell stocks can use the coming numbers to test whether growth is holding.

Why Do Apparel Export, Pharma and Defence Cell Stocks Have a Strong Roadmap in India?

Apparel export, pharma and defence cell stocks have a strong roadmap in India because strong global sourcing from India, wider access to quality medicines and rising defence and railway spending keep widening the market for these companies.

  • Garments export. Global brands source more from India.
  • Generic pharma. Patients need affordable medicines.
  • Batteries and defence electronics. Defence and rail need advanced systems.

Why Pearl Global Industries Features Among These Apparel Export, Pharma and Defence Cell Stocks

Among the apparel export, pharma and defence cell stocks on this list, Pearl Global Industries is a Gurugram-based apparel manufacturer and exporter that makes garments for leading international brands from factories in India, Bangladesh, Vietnam and Indonesia.

In the June 2026 quarter, revenue grew 24.2% year on year to Rs 1,539 crore, while net profit rose 51.4% to Rs 99.2 crore. Revenue rose from Rs 2,747 crore in FY22 to Rs 5,062 crore in FY26, a compound annual growth rate of 16.5%.

Net profit grew from Rs 70.1 crore in FY22 to Rs 270 crore in FY26, which works out to a compound annual growth rate of 40.1%. The company has a return on equity of 19.0%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 11,806 crore. The stock trades at a P/E of 38.9, above the industry P/E of 35.2.

Roadmap: The company benefits from global brands diversifying their sourcing away from a single country, and its multi-country footprint helps it serve them. Capacity additions and a growing retail brand portfolio add to its growth levers.

What to watch: Watch order inflow from global brands and the ramp-up of newer factories.

Why Strides Pharma Science Features Among These Apparel Export, Pharma and Defence Cell Stocks

Among the garment exporter, medicine maker and cell shares on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.

The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.

Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.

Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

What to watch: Track new US launches and the pace of price erosion in generic categories.

Why HBL Engineering Features Among These Apparel Export, Pharma and Defence Cell Stocks

Among the three companies on this list, HBL Engineering, formerly HBL Power Systems, makes specialised batteries, defence electronics, railway safety systems, and electronics for aerospace and industrial use.

Revenue rose from Rs 1,251 crore in FY22 to Rs 3,362 crore in FY26, a compound annual growth rate of 28.0%. Net profit grew from Rs 93.7 crore in FY22 to Rs 814 crore in FY26, which works out to a compound annual growth rate of 71.7%.

In the June 2026 quarter, revenue grew 6.0% year on year to Rs 659 crore. The company has a return on equity of 36.8%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 22,507 crore. The stock trades at a P/E of 28.8, below the industry P/E of 36.9.

Roadmap: The company has grown its defence electronics and railway safety businesses, including systems for collision avoidance, and is expanding its battery lines. Orders from railways and defence customers provide a long runway.

What to watch: Monitor large railway and defence orders and their execution schedules.

Pearl Global Industries vs Strides Pharma Science vs HBL Engineering on Key Financials

The table below sets the three apparel export, pharma and defence cell stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Pearl Global Industries 2,747 5,062 16.5% 270 5.3%
Strides Pharma Science 3,202 5,009 11.8% 575 11.5%
HBL Engineering 1,251 3,362 28.0% 814 24.2%

HBL Engineering posts the highest return on equity in this group at 36.8%. Pearl Global Industries has the largest FY26 revenue at Rs 5,062 crore, and HBL Engineering shows the fastest revenue growth with a 28.0% compound annual rate. A useful habit with apparel export, pharma and defence cell stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several readymade garments, generics and power storage stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Company Q1 FY26 Revenue (Rs Cr) Q1 FY27 Revenue (Rs Cr) Year-on-Year Growth
Pearl Global Industries 1,239 1,539 24.2%
Strides Pharma Science 1,128 1,270 12.6%
HBL Engineering 621 659 6.0%

Key Risks to Check Before Investing in Apparel Export, Pharma and Defence Cell Stocks

Every theme carries risks that deserve a check before any decision. For these apparel export, pharma and defence cell stocks, the main points are: Long-term garment exporter, medicine maker and cell shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Currency moves. Export earnings move with the rupee.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Order timing. Defence and space orders can shift between periods.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter apparel export, pharma and defence cell stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Apparel Export, Pharma and Defence Cell Stocks

Apparel export, pharma and defence cell stocks work best when investors track growth, valuation and return on equity side by side. Pearl Global Industries, Strides Pharma Science and HBL Engineering each have a clear plan to grow. Based on the 13 November 2026 close, Pearl Global Industries trades at Rs 1,333.1, Strides Pharma Science at Rs 1,014.6 and HBL Engineering at Rs 799.55. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these apparel export, pharma and defence cell stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track apparel export, pharma and defence cell stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are apparel export, pharma and defence cell stocks?

Ans. Apparel export, pharma and defence cell stocks are listed companies that design and export readymade garments to global brands, make generic medicines and ingredients, and make industrial batteries, defence electronics and railway safety systems. Their earnings depend on export orders, medicine demand and defence and rail orders. This list looks at three of them, Pearl Global Industries, Strides Pharma Science and HBL Engineering, using reported FY22 to FY26 financials and the 13 November 2026 closing prices.

Which apparel export, pharma and defence cell stocks are covered in this list?

Ans. This list covers Pearl Global Industries, Strides Pharma Science and HBL Engineering. Based on the 13 November 2026 close, Pearl Global Industries traded at Rs 1,333.1, Strides Pharma Science at Rs 1,014.6 and HBL Engineering at Rs 799.55. Their return on equity ranges from 17.9% to 36.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 28.0%.

Why do apparel export, pharma and defence cell stocks have a strong future roadmap in India?

Ans. Apparel export, pharma and defence cell stocks have a strong roadmap in India because strong global sourcing from India, wider access to quality medicines and rising defence and railway spending keep widening the market for these companies. The main drivers are as follows. Garments export. Global brands source more from India. Generic pharma. Patients need affordable medicines. Batteries and defence electronics. Defence and rail need advanced systems. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Pearl Global Industries performed financially?

Ans. Revenue rose from Rs 2,747 crore in FY22 to Rs 5,062 crore in FY26, a compound annual growth rate of 16.5%. Net profit grew from Rs 70.1 crore in FY22 to Rs 270 crore in FY26, which works out to a compound annual growth rate of 40.1%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 1,539 crore, while net profit rose 51.4% to Rs 99.2 crore. The company has a return on equity of 19.0%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 11,806 crore. The stock trades at a P/E of 38.9, above the industry P/E of 35.2. Looking ahead, the company benefits from global brands diversifying their sourcing away from a single country, and its multi-country footprint helps it serve them. Capacity additions and a growing retail brand portfolio add to its growth levers.

How has Strides Pharma Science performed financially?

Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

How has HBL Engineering performed financially?

Ans. Revenue rose from Rs 1,251 crore in FY22 to Rs 3,362 crore in FY26, a compound annual growth rate of 28.0%. Net profit grew from Rs 93.7 crore in FY22 to Rs 814 crore in FY26, which works out to a compound annual growth rate of 71.7%. In the June 2026 quarter, revenue grew 6.0% year on year to Rs 659 crore. The company has a return on equity of 36.8%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 22,507 crore. The stock trades at a P/E of 28.8, below the industry P/E of 36.9. Looking ahead, the company has grown its defence electronics and railway safety businesses, including systems for collision avoidance, and is expanding its battery lines. Orders from railways and defence customers provide a long runway.

What risks should investors check before buying apparel export, pharma and defence cell stocks?

Ans. Investors should check a few risks before buying apparel export, pharma and defence cell stocks. Currency moves. Export earnings move with the rupee. Regulatory approvals. Plant inspections and approvals can affect supplies. Order timing. Defence and space orders can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of apparel export, pharma and defence cell stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 13 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



apparel export Best Stocks garment exporter generics and power storage stocks HBL Engineering medicine maker and cell shares Pearl Global Industries pharma and defence cell stocks readymade garments Strides Pharma Science
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply